Antibody-mediated rejection—treatment standard
Nephrology Dialysis Transplantation · 01.08.2025 · 40 (8) · 1615-1627
DOI: 10.1093/ndt/gfaf097 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 29.05.2025. Verfasst von Georg A Böhmig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Graft Rejection, Kidney Transplantation. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-mediated rejection (AMR) remains a major cause of graft failure, with significant health and economic burden. Despite being recognized >25 years ago, AMR treatment remains unstandardized, and no therapy has gained robust regulatory approval. While uncontrolled series have shown promise, few well-designed trials exist, with most yielding negative results. In the absence of strong trial data, a Transplantation Society expert consensus recommended potential treatment options with low levels of evidence, tailored to clinical phenotypes. Here, we re-evaluate the current evidence for AMR treatment decisions. We conclude that steroids, rituximab, bortezomib, and interleukin-6 (IL-6) antagonists lack sufficiently robust evidence to support their use in AMR. For early AMR, antibody depletion using immunoadsorption could be considered as an alternative to plasmapheresis. High-dose intravenous immunoglobulin (IVIG) may be added, though the supporting evidence remains limited. While previous trials primarily targeted the cause of AMR, recent data on the successful reversal of AMR activity by CD38 antibodies—particularly recent phase 2 trial results—suggest that targeting the cellular inflammation resulting from antibody binding to the endothelium could be a rational approach. Along these lines, in severe early AMR, complement inhibition may also be an option. Ongoing phase 2 trials evaluating prolonged courses of high-dose IVIG, the neonatal Fc receptor blocker efgartigimod, the tyrosine kinase inhibitor fostamatinib, and the complement inhibitor BIVV020, along with phase 3 trials of the anti-IL-6 receptor antibody tocilizumab and the CD38 antibody felzartamab, offer hope for effective, approved therapies targeting different aspects of AMR pathobiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation, Centre Hospitalier Universitaire Grenoble-Alpes, France.
- Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
ORCID-Profile: Matthias Diebold, Lionel Rostaing, Klemens Budde
Zitieren
APA
Böhmig, G. A., Naesens, M., Viklicky, O., Thaunat, O., Diebold, M., Rostaing, L., & Budde, K. (2025). Antibody-mediated rejection—treatment standard. Nephrology Dialysis Transplantation, 40(8), 1615-1627. https://doi.org/10.1093/ndt/gfaf097
Vancouver
Böhmig GA, Naesens M, Viklicky O, Thaunat O, Diebold M, Rostaing L, et al. Antibody-mediated rejection—treatment standard. Nephrology Dialysis Transplantation. 2025;40(8):1615-1627. doi:10.1093/ndt/gfaf097
BibTeX
@article{Bhmig2025,
author = {Böhmig, Georg A and Naesens, Maarten and Viklicky, Ondrej and Thaunat, Olivier and Diebold, Matthias and Rostaing, Lionel and Budde, Klemens},
title = {Antibody-mediated rejection—treatment standard},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {8},
pages = {1615--1627},
doi = {10.1093/ndt/gfaf097}
}
EUVIMED